Last week, we witnessed a roller coaster ride in one of our largest holdings, NexOptic Technology (NXO). Here’s the scoop on what happened, as we explain the tactics of how big money firms short stocks. But don’t tell anyone, it’s supposed to be a secret…
3D Signatures Inc. announces clinical study results which confirm that based on a swab from the inside of a patient’s cheek, its proprietary TeloView™ software platform has the ability to identify patients with Alzheimer’s disease (“AD”) and, furthermore, distinguish between mild, moderate, and severe forms of the disease. The results of this confirmatory study have been accepted for publication in the peer-reviewed Journal of Alzheimer’s Disease.
In exactly one month, NexOptic Technology Corp., together with Spectrum Optix, are going to reveal something really special – the world’s first-ever “flattened” telescope. You don’t want to miss it.
NexOptic Technology Corp. and Spectrum Optix Inc. are about to announce a major breakthrough at a media event to be held at the H.R. MacMillan Space Centre in Vancouver, British Columbia.The theme of the evening is “Flattening the Telescope,” and will mark the Companies’ first step in transforming what they believe may redefine many additional optical applications by utilizing their patent-pending Blade Optics™ lens technology.
We asked past president of the Calgary Centre of the Royal Astronomical Society of Canada, Larry McNish, to take the Blade Optics prototype for a spin. Here’s what he had to say.
NexOptic has been selected for inclusion in the 2017 TSX Venture 50®, a ranking of the top performers on the TSX Venture Exchange. NexOptic is ranked second overall in the technology sector. Here’s a video on why the Company outperformed.
3D Signatures Inc. just told the world that the results of a prospective blood-based prostate cancer pilot study using the Company’s proprietary TeloViewTM software platform was a perfect 50/50. Based on blinded blood samples, TeloViewTM correctly predicted the stability and aggressiveness of disease for each of the study’s 50 intermediate risk prostate cancer patients.
NexOptic Technology Corp. and Spectrum Optix Inc. of Calgary, Canada tells the world that they have completed assembly of their proof of concept telescope prototype lens stack and successfully captured its first set of unprocessed images of the moon.
Here’s a look at the current state of our Cashless Society, what it means, and the companies and governments behind this revolution.
In less than 60 days, we are about to witness the unveiling of a revolutionary flat lens system that threatens the very basic concepts of physics. Here is another look at one of our favourite technology plays and what to expect.
NexOptic Technology Corp. and Spectrum Optix Inc. of Calgary, Canada, and together with NexOptic, the “Companies” are pleased to announce that Mr. Stephen Petranek has joined the Board of Directors of NexOptic Technology Corp.
Data from a new study1 published recently in Urologic Oncology involving men with localized high-risk prostate cancer suggests that the use of 3D Signatures Inc.’s technology platform, TeloView™, may be a promising blood-based treatment-response biomarker in prostate cancer patients who are undergoing combined (hormonal) androgen deprivation therapy and radiation therapy.